Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
07:01pm, Thursday, 09'th Jan 2025
In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPA
02:35am, Tuesday, 07'th Jan 2025
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS), the largest shareholder in HOOKIPA Pharma, has thrown its backing behind the proposed merger with Poolbeg Pharma PLC (AIM:POLB). Gilead, which holds just un
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
07:11pm, Friday, 03'rd Jan 2025
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.
Jefferies Top 2025 Stock Picks Include 5 Sizzling Large Cap Dividend Blue Chips
04:05pm, Friday, 03'rd Jan 2025
As the calendar turns over to 2025, the leading Wall Street firms are releasing their top stock picks for the new year.
Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise
03:51am, Sunday, 29'th Dec 2024
Gilead's stock is rated a "buy" due to its thriving HIV business, promising oncology pipeline, and potential for long-term growth despite some volatility. The company's Q3 earnings show strong perform
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
10:01am, Thursday, 26'th Dec 2024
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
8 Trading Lessons to Take From Our 2024 Stock Picks
09:59am, Tuesday, 24'th Dec 2024
Subscribers to Chart of the Week received this commentary on Sunday, December 8.
Gilead Sciences to Present at Upcoming Investor Conference
04:05pm, Friday, 20'th Dec 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Con
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
02:00pm, Friday, 20'th Dec 2024
GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
Cash is Down, Valuations Are Up, but Stay Invested
07:04pm, Thursday, 19'th Dec 2024
Bullish sentiment rules
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
11:15am, Wednesday, 18'th Dec 2024
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.
5 High Earnings Yield Value Picks to Buy for 2025
09:10am, Wednesday, 18'th Dec 2024
Unlock your portfolio value with these high earnings yield value stocks, PBI, GPOR, KINS, NATL and GILD.
Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure
01:53am, Wednesday, 18'th Dec 2024
Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined with Gi
4 Big Drug Stocks That May Continue to Outperform in 2025
11:06am, Tuesday, 17'th Dec 2024
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (
